Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling

International Journal of Cancer

Volumn 121, Issue 8, 2007, Pages 1821-1829

  Albihn, Ami ^a   Mo, Hao ^a   Yang, Ying ^a,b   Henriksson, Marie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Bax; Camptothecin; Myc; Paclitaxel; PKC

Indexed keywords

CAMPTOTHECIN; CASPASE 3; CASPASE 9; MYC PROTEIN; PACLITAXEL; PROTEIN BAX; PROTEIN BID; PROTEIN KINASE C DELTA; PROTEIN P53;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLOTTING, WESTERN; CAMPTOTHECIN; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; GENES, MYC; HUMANS; MITOCHONDRIA; NEUROBLASTOMA; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 34548675554     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22866     Document Type: Article

References (47)

1. Hooker CW, Hurlin PJ. Of Myc and Mnt. J Cell Sci 2006;119:208-16.
2. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
3. Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 2003;197:173-9.
4. Peltenburg LT, de Bruin EC, Meersma D, Wilting S, Jurgensmeier JM, Schrier PI. c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers. Melanoma Res 2004;14:3-12.
5. Fulda S, Lutz W, Schwab M, Debatin KM. MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 1999;18:1479-86.
6. Soucie EL, Annis MG, Sedivy J, Filmus J, Leber B, Andrews DW, Penn LZ. Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. Mol Cell Biol 2001;21:4725-36.
7. Grassilli E, Ballabeni A, Maellaro E, Del Bello B, Helin K. Loss of MYC confers resistance to doxorubicin-induced apoptosis by preventing the activation of multiple serine protease- and caspase-mediated pathways. J Biol Chem 2004;279:21318-26.
8. Albihn A, Loven J, Ohlsson J, Osorio LM, Henriksson M. c-Myc-dependent etoposide-induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling. J Cell Biochem 2006;98:1597-614.
9. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-28.
10. Zunino F, Pratesi G. Camptothecins in clinical development. Expert Opin Invest Drugs 2004;13:269-84.
11. Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, Aranes MJ, Augenlicht LH. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003;89:1757-65.
12. Bottone MG, Soldani C, Tognon G, Gorrini C, Lazze MC, Brison O, Ciomei M, Pellicciari C, Scovassi AI. Multiple effects of paclitaxel are modulated by a high c-myc amplification level. Exp Cell Res 2003;290:49-59.
13. Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, Evan G. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol 2002;22:6158-69.
14. Iaccarino I, Hancock D, Evan G, Downward J. c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Cell Death Differ 2003;10:599-608.
15. Simonian PL, Grillot DA, Nunez G. Bak can accelerate chemotherapy-induced cell death independently of its heterodimerization with Bcl-XL and Bcl-2. Oncogene 1997;15:1871-5.
16. Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998;58:4776-81.
17. Liu QY, Stein CA. Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. Clin Cancer Res 1997;3:2039-46.
18. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, ChoChung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18:3509-17.
19. Perkins CL, Fang G, Kim CN, Bhalla KN. The role of Apaf-1, caspase-9, and bid proteins in etoposide- or paclitaxel-induced mitochondrial events during apoptosis. Cancer Res 2000;60:1645-53.
20. Lamparska-Przybysz M, Gajkowska B, Motyl T. Cathepsins and BID are involved in the molecular switch between apoptosis and autophagy in breast cancer MCF-7 cells exposed to camptothecin. J Physiol Pharmacol 2005;56 (Suppl 3): 159-79.
21. Brodie C, Blumberg PM. Regulation of cell apoptosis by protein kinase c delta. Apoptosis 2003;8:19-27.
22. Matassa AA, Carpenter L, Biden TJ, Humphries MJ, Reyland ME. PKCδ is required for mitochondrial-dependent apoptosis in salivary epithelial cells. J Biol Chem 2001;276:29719-28.
23. Koriyama H, Kouchi Z, Umeda T, Saido TC, Momoi T, Ishiura S, Suzuki K. Proteolytic activation of protein kinase C delta and epsilon by caspase-3 in U937 cells during chemotherapeutic agent-induced apoptosis. Cell Signal 1999;11:831-8.
24. Lewis AE, Susarla R, Wong BC, Langman MJ, Eggo MC. Protein kinase C delta is not activated by caspase-3 and its inhibition is sufficient to induce apoptosis in the colon cancer line, COLO 205. Cell Signal 2005;17:253-62.
25. Song MG, Gao SM, Du KM, Xu M, Yu Y, Zhou YH, Wang Q, Chen Z, Zhu YS, Chen GQ. Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase Cδ-dependent mechanisms. Blood 2005;105:3714-21.
26. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
27. Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M. c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets. Genes Dev 1998;12:3797-802.
28. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000;6:1389-99.
29. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
30. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S, Metzgar R, Aulakh G, Ting R, Ruscetti F, Gallo R. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979;54:713-33.
31. Jensen FC, Girardi AJ, Gilden RV, Koprowski H. Infection of Human and Simian Tissue Cultures with Rous Sarcoma Virus. Proc Natl Acad Sci USA 1964;52:53-9.
32. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA 2006;103:6344-9.
33. Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J, Einhom S, Grander D. Mechanisms of Interferon-α induced apoptosis in malignant cells. Oncogene 2002;21:1251-62.
34. Xu D, Popov N, Hou M, Wang Q, Bjorkholm M, Gruber A, Menkel AR, Henriksson M. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci USA 2001;98:3826-31.
35. Wood DE, Newcomb EW. Cleavage of Bax enhances its cell death function. Exp Cell Res 2000;256:375-82.
36. Stahl M, Kasimir-Bauer S, Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drugs 1997;8:671-6.
37. Jiang JF, Liu WJ, Ding J. Regulation of telomerase activity in camptothecin-induced apoptosis of human leukemia HL-60 cells. Acta Pharmacol Sin 2000;21:759-64.
38. Persaud SD, Hoang V, Huang J, Basu A. Involvement of proteolytic activation of PKCdelta in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. Int J Oncol 2005;27:149-54.
39. Zhang J, Liu N, Zhang J, Liu S, Liu Y, Zheng D. PKCdelta protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. J Cell Biochem 2005;96:522-32.
40. Lindsten T, Thompson CB. Cell death in the absence of Bax and Bak. Cell Death Differ 2006;13:1272-6.
41. Nesbit CE, Grove LE, Yin X, Prochownik EV. Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins. Cell Growth Differ 1998;9:731-41.
42. Park SJ, Wu CH, Gordon JD, Zhong X, Emami A, Safa AR. Taxol induces caspase-10-dependent apoptosis. J Biol Chem 2004;279:51057-67.
43. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997;57:1109-15.
44. Yoshida K, Liu H, Miki Y. Protein kinase C delta regulates Ser46 phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage. J Biol Chem 2006;281:5734-40.
45. Pommier Y, Kerrigan D, Hartman KD, Glazer RI. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 1990;265:9418-22.
46. Hotti A, Jarvinen K, Siivola P, Holtta E. Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases. Oncogene 2000;19:2354-62.
47. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61.